The Global Lupus Therapeutic Market is estimated to be valued at US$ 3035.59 Mn or Million in 2023 and is expected to exhibit a CAGR of 8.6% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Overview:
Lupus therapeutic drugs are immunosuppressant medications prescribed to reduce symptoms and help control disease activity in patients suffering from systemic lupus erythematosus (SLE). Biologics inhibit specific molecules involved in immune system processes to alleviate inflammation.
Market key trends:
One of the key trends in the lupus therapeutic market is the rise in development of biosimilar drugs. Biosimilars are biologic medical products that are highly similar to an already licensed biological drug (known as reference product) and have no clinically meaningful differences in terms of safety, purity, and potency. Biosimilars offer considerable cost savings compared to reference biologics and their uptake is increasing. This is expected to fuel the market growth over the forecast period.
Segment Analysis
The global lupus therapeutics market is segmented based on drug class, route of administration, disease type, distribution channel, and geography. Based on drug class, the market is segmented into corticosteroids, nonsteroidal anti-inflammatory drugs (NSAIDs), immunosuppressive drugs, cytotoxics drugs, and others. Corticosteroids segment currently dominates the market due to high usage of corticosteroids drugs such as prednisone in managing mild to moderate lupus cases.
Key Takeaways
The Global Lupus Therapeutic Market is expected to witness high growth, exhibiting CAGR of 8.6% over the forecast period, due to increasing prevalence of lupus disease worldwide.
Regional analysis:
North America region is expected to dominate the global lupus therapeutics market during the forecast period owing to increasing awareness regarding lupus in the region and presence of major market players. Asia Pacific region is projected to be the fastest growing market due to improving healthcare infrastructure and rising adoption of advanced therapeutic drugs.
Key players
Key players operating in the lupus therapeutics market are Hikma Pharmaceuticals PLC, Lupus Therapeutics, Dr. Reddy's Laboratories Ltd., GlaxoSmithKline plc, Amgen Inc., Novartis AG, Sanofi, UCB S.A., ImmuPharma PLC, Bayer AG, Merck & Co., Inc., Aurinia Pharmaceuticals Inc., Pfizer Inc., ADMA Biologics, Inc., AstraZeneca, F.Hoffmann-La Roche Ltd, Bristol-Myers Squibb Company, Teva Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, and Boehringer Ingelheim International Gmbh.
Comments
0 comment